October 21, 2014 5:53 PM ET

Biotechnology

Company Overview of Aldagen, Inc.

Company Overview

Aldagen, Inc., a biopharmaceutical company, develops adult stem cell products for tissue repair and regeneration. The company focuses on developing product candidates to address cardiovascular disease. It develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. It also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Its therapeutic markets include critical limb ischemia, ischemic heart failure, and ischemic stroke. Aldagen, Inc. was formerly known as Stemco Biomedical, Inc. and changed its name to Aldagen, Inc. in November, 2005. The company was inc...

2810 Meridian Parkway

Suite 148

Durham, NC 27713

United States

Founded in 2000

24 Employees

Phone:

919-484-2571

Fax:

919-484-8792

Key Executives for Aldagen, Inc.

Scientific Founder and Member of Medical Advisory Board
Scientific Founder and Member of Medical Advisory Board
Scientific Founder
Chief Financial Officer and Principal Accounting Officer
Age: 62
Chief Medical Officer
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Avecia Biotechnology, Inc. United States
Signalway Antibody Co.,Ltd United States
Dermal Sciences, Inc. United States
Bayhill Therapeutics, Inc. United States
Locus Development Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aldagen, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.